The big positive in this release is, as KPKG has continually emphasised, the early access information. With a potential 200 patients at in my mind up to $10,000 profit per person this gives a steady income stream. Over time it will also help validate the drug singularly to a phase 3 study.
Ann: Company Update, page-8
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.015(13.0%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $612.7K | 4.843M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56662 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 600000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |